LianBio
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIANY research report →
About the company
LianBio is a biopharmaceutical firm dedicated to advancing and marketing therapeutic agents across various critical health sectors, including cardiovascular disorders, oncology, ophthalmological conditions, and inflammatory ailments. Its operations are primarily concentrated in China and the broader Asian region. The company's pipeline features several promising drug candidates targeting a range of severe illnesses.
- CEO
- Adam Leo Stone
- IPO
- 2021
- Employees
- 163
- HQ
- Princeton, NJ, US
Price Chart
- Market Cap
- $12.55M
- P/E
- 2.56
- P/S
- 0.00
- P/B
- 0.61
- EV/EBITDA
- -2.49
- Div Yield
- 373.91%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 11.78%
- ROIC
- -6.19%
- Revenue
- $0 · 0.00%
- Net Income
- $4.91M · 98.32%
- EPS
- $0.04 · 96.51%
- Op Income
- $-1,270,350
- FCF YoY
- 32.14%
- 52W High
- $0.44
- 52W Low
- $0.03
- 50D MA
- $0.13
- 200D MA
- $0.10
- Beta
- 0.04
- Avg Volume
- 4.05K
Get TickerSpark's AI analysis on LIANY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LIANY coverage
Recent articles, reports, and earnings notes.
No research on LIANY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LIANY report →Similar companies
Peers in the same neighborhood.